Ignite Creation Date:
2024-05-06 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04722172
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-18
First Post:
2021-01-20
Brief Title:
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLLSLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety of limiting treatment time with acalabrutinib and obinutuzumab in people who have chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL The researchers want to find out whether stopping the study drugs when the cancer responds to the treatment followed by a period of observation in which no treatment is given is better than the same as or worse than the usual approach A usual treatment for CLL and SLL is to give the study drugs continuously until the cancer progresses even if the disease is in remission But when people receive these drugs for long periods of time they can have serious side effects and their cancer can become resistant to treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None